Treating Multiple Myeloma in Latin America

Interactive discussions and expert insights on the latest updates and remaining challenges

Overview

In recent years, progress in the understanding of multiple myeloma has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Multiple Myeloma Academy to help physicians who treat multiple myeloma bridge the gap between innovation and implementation of patient care.

Date and Location

23–24 June 2022, Virtual Meeting

Meeting Content

View the slides and watch the video of Day 1

Meeting Content

View the slides and watch the video of Day 2

Chair

Rafael Fonseca

Rafael Fonseca, MD

Mayo Clinic Cancer Center, USA

Faculty

Keith Stewart

Keith Stewart, MBChB, MBA

Princess Margaret Cancer Centre, Canada

Sagar Lonial

Sagar Lonial, MD, FACP

Emory University School of Medicine, USA

Vania Hungria

Vania Hungria, MD

São Germano Clinic, Brazil

Eloisa Riva

Eloisa Riva, MD

Hospital de Clínicas, Montevideo, Uruguay

Luciano J. Costa

Luciano J. Costa, MD, PhD

University of Alabama, Birmingham, USA

Agenda

This virtual program will be held over 2 days.

Day 1: Thursday, 23 June 2022

11.30 AM – 3.00 PM (MST/Arizona)
1.30 PM5.00 PM (GMT-5/Colombia)
2.30 PM – 6.00 PM (GMT-4/Chile)
3.30 PM – 7.00 PM (GMT-3/Brazil)

Time (UTC -3) Topic Speaker
3.30 PM – 3.40 PM Welcome and Meeting Overview
• Introduction to audience response system (ARS)
Rafael Fonseca, MD
3.40 PM – 4.00 PM Diagnosis and Risk Stratification of Multiple Myeloma
• Prognostic value, clinical relevance, and response-adapted therapeutic strategies
Vania Hungria, MD, PhD
4.00 PM – 4.25 PM Smoldering Multiple Myeloma: Current and Future Developments
• Diagnosis, criteria, and pragmatic treatment approaches
Sagar Lonial, MD, FACP
4.25 PM – 4.50 PM Newly Diagnosed Transplant-Eligible Multiple Myeloma: Frontline Therapy and the Role of Transplantation
• Updates, induction therapies, and knowing when to transplant
Luciano Costa, MD, PhD
4.50 PM – 5.10 PM Debate
• Is myeloma curable or not?
Rafael Fonseca, MD (yes) vs Eloisa Riva, MD (no)
5.10 PM – 5.20 PM Break  
5.20 PM – 5.45 PM Advances in Consolidation and Maintenance Therapy: Latest Updates and MRD-Guided Therapy
• Evolving insights in consolidation and maintenance treatment after transplant
Luciano Costa, MD, PhD
5.45 PM – 6.10 PM Treatment Considerations for Newly Diagnosed Transplant-Ineligible Patients
• Criteria, guidelines, and treatment choices
Keith Stewart, MBChB, MBA
6.10 PM – 6.35 PM Interactive Discussion and Q&A
• Regional challenges of MM diagnosis (2–3 questions to trigger discussion, no presentation slides)
• Questions from audience
All faculty discussion
6.35 PM – 6.55 PM Debate
• Smoldering myeloma: To treat or not to treat?
Sagar Lonial, MD, FACP (yes) vs Keith Stewart, MBChB, MBA (no)
6.55 PM – 7.00 PM Session Close
• ARS questions
Rafael Fonseca, MD

Day 2: Friday, 24 June 2022

11.30 AM – 3.00 PM (MST/Arizona)
1.30 PM – 5.00 PM (GMT-5/Colombia)
2.30 PM – 6.00 PM (GMT-4/Chile)
3.30 PM – 7.00 PM (GMT-3/Brazil)

Time (UTC-3) Topic Speaker
3.30 PM – 3.40 PM Session Open Rafael Fonseca, MD
3.40 PM – 4.00 PM Defining and Understanding High-Risk Multiple Myeloma
• Risk stratification, prognosis, and therapy choices
Eloisa Riva, MD
4.00 PM – 4.25 PM Early Relapse of Multiple Myeloma: Current and Emerging Treatment Options
• Definition, prognosis, updated treatment approaches
Rafael Fonseca, MD
4.25 PM – 4.45 PM Patient Case Discussion and Q&A: Relapsed/Refractory Multiple Myeloma
• Case 1 from the region
Regional case presenter
Ana Luiza Silva, MD
4.45 PM – 4.55 PM Break  
4.55 PM – 5.20 PM Management of Heavily Pretreated Multiple Myeloma
• Optimal use of treatment choices in relapsed/refractory multiple myeloma
Keith Stewart, MBChB, MBA
5.20 PM – 5.40 PM Patient Case Discussion and Q&A: Relapsed/Refractory Multiple Myeloma
• Case 2 from the region
Regional case presenter
Lucía Pérez, MD
5.40 PM – 6.30 PM Beyond the Horizon: New and Future Multiple Myeloma Treatment Approaches
• Optimal use of treatment choices in relapsed/refractory multiple myeloma
– Bispecifics in multiple myeloma
– CAR Ts in multiple myeloma
Vania Hungria, MD, PhD (bispecifics), Luciano Costa, MD, PhD (CAR T)
6.30 PM – 6.55 PM Interactive Discussion and Q&A
• Treatment landscape evolution (2–3 questions to trigger discussion, no presentation slides)
• Questions from audience
All faculty discussion
6.55 PM – 7.00 PM Session Close Rafael Fonseca, MD